<?xml version="1.0" encoding="UTF-8"?>
<p>To investigate the possible roles of FXR in gastric cancer, the viability of SGC-7901 cells was analyzed following treatment with z-guggulsterone, an FXR antagonist. The results indicated that z-guggulsterone led to dose-dependent cytotoxicity in SGC7901 cells (
 <xref ref-type="fig" rid="fig1">Figure 1(b)</xref>). The survival rate of SGC-7901 cells was approximately 50%, while GES-1 cells were only minimally affected by incubation with 75 
 <italic>µ</italic>M z-guggulsterone (
 <xref ref-type="fig" rid="fig1">Figure 1(b)</xref>). This indicated that z-guggulsterone targets tumor cells with less cytotoxicity to gastric epithelial cells, suggesting z-guggulsterone may be a safe and useful anticancer compound.
</p>
